Project Grant R01HL180497
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $756K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $747,953 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for investigator-initiated research on lung-resident memory TH2 cells in asthma. The project, R01AI192629, identifies pathways that mediate survival and maintenance of allergen-specific tissue-resident memory TH2 cells in specialized niches within the asthmatic lung. The research focuses on the CXCR6...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $1,579,554 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 10, 2025, to conduct multi-trait, multi-ancestry, and multi-omic genetic studies of chronic obstructive pulmonary disease (COPD) and asthma using data integrated across global biobanks. The work integrates genetic and phenotypic data from the All of Us Research Program,...
- Federal Grant Award Summary Award Details: Massachusetts General Hospital (The General Hospital Corporation) received a $250,000 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 1, 2025, with completion anticipated July 31, 2026. Research Objectives and Deliverables: This grant supports biomedical research investigating lung-resident memory T helper type 2 (TH2) cells as novel...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $100,228 on September 30, 2026, for research into mechanisms regulating regulatory T cell (Treg) tissue responses driven by IL-33 in the lung under the Cardiovascular Diseases Research program (CFDA 93.837). The research addresses acute lung injury and acute respiratory distress syndrome by investigating how IL-33 stimulation enhances Treg reparative capacity. The investigator's preliminary data demonstrate that...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $770,247 on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define the mechanistic basis of airway metaplastic response through investigation of stem cell heterogeneity, YAP signaling, and EGFR signaling pathways. The research addresses the cellular source and molecular mechanisms governing squamous and mucous metaplasia—two...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $736,411 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of neutrophil-derived resistin-like molecule G (RELMG) in arrhythmia pathogenesis and prevention. The research examines RELMG's mechanism of action and therapeutic potential in reducing ventricular tachycardia and atrial fibrillation following...
- The National Heart, Lung, and Blood Institute awarded University of Massachusetts Medical School $103,686 on December 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support basic research into translation control mechanisms in heart and lung disease. The funded research investigates how the RNase A family nuclease angiogenin stimulates blood vessel formation and why angiogenin dysfunction associates with heart failure, and separately examines how the bacterial...
- The National Institute of Allergy and Infectious Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $247,500 on July 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a microfluidic assay for detecting neutrophil extracellular traps in bronchoalveolar lavage fluid from lung transplant patients. The project addresses chronic lung allograft dysfunction, a progressive scarring condition that limits survival in lung...
- The National Heart Lung and Blood Institute awarded Northwestern University $654,762 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate regulatory T cell mechanisms limiting persistent inflammation during recovery from viral pneumonia. The award funds research into how FOXP3+ regulatory T cells orchestrate lung repair after viral pneumonia through expression of suppressive mediators, particularly the anti-inflammatory cytokine interleukin-10. The...
- The National Heart Lung and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $330,176 on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct mentored research on the effect of severe obesity on regional lung perfusion in acute hypoxemic respiratory failure. The award funds two primary research aims. Aim 1 defines the association between severe obesity and regional lung perfusion in a novel...